A Clinical Evaluation of the RheOx Bronchial Rheoplasty System for the Treatment of the Symptoms of Chronic Bronchitis in Adult Patients With COPD (GALA RheSolve)

This is a prospective, randomized, parallel group, double-blind, sham-controlled, multicenter clinical trial to assess the safety and effectiveness of Bronchial Rheoplasty for the treatment of the symptoms of chronic bronchitis in moderate to severe COPD.

Bronchial rheoplasty is a staged procedure wherein pulsed electric fields are delivered to the goblet cells in the airways of right lung in the first treatment visit, and then the left lung is treated approximately 1 month later.

End Points
  • Change in CAT score at 6 months
  • Rate of moderate and severe COPD exacerbations
Mucus obstruction resulting in shortness of breath and cough.



RheOx delivers non-thermal pulsed electric fields to the airyways to reduce mucus producing cells in patients with Chronic Bronchitis
Cells regenerate with fewer abnormal cells, therefore producing less mucus


Key inclusion criteria are:
  • Post-bronchodilator FEV1 ≥ 30%
  • Chronic Bronchitis
  • LAMA and/or LABA +/- ICS maintenance inhaler therapy for at least 2 months
  • former ≥ 10 pack year smoking
ClinicalTrials.gov Identifier: NCT04677465

For more detailed information on this trial please click the link above to visit ClinicalTrials.gov

© 2025 Emphysema COPD Research Center

Thank You

For Contacting Us!

We’ll Respond to Your Message as Soon as Possible!